Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Debt: 2024

Historic Total Debt for Apellis Pharmaceuticals (APLS) over the last 1 years, with Dec 2024 value amounting to $359.5 million.

  • Apellis Pharmaceuticals' Total Debt rose 26.66% to $454.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $454.7 million, marking a year-over-year increase of 26.66%. This contributed to the annual value of $359.5 million for FY2024, which is N/A change from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Total Debt stood at $359.5 million for FY2024.
  • In the past 5 years, Apellis Pharmaceuticals' Total Debt registered a high of $359.5 million during FY2024, and its lowest value of $359.5 million during FY2024.
  • For the 1-year period, Apellis Pharmaceuticals' Total Debt averaged around $359.5 million, with its median value being $359.5 million (2024).